[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100399655":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":26,"responsibleParty":41,"collaborators":44,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":52,"sex":58,"minAge":59,"maxAge":10,"enrollmentInfo":60,"targetDuration":10,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":72,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Erasmus Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Routine clinical care with Genotropin treatment",null,"Data collection throughout routine clinical care with subcutaneous injections Genotropin, 0.6-0.8 mg\u002Fday. Participants start with 0.2 mg\u002Fday and the dose increases with 0.2 mg\u002Fday per month to a maximum dose of 0.6-0.8 mg\u002Fday.",[13],{"name":14,"affiliation":15,"role":16},"Laura de Graaff, MD, PhD","Erasmus MC, University Medical Center Rotterdam","PRINCIPAL_INVESTIGATOR",[18,22],{"name":14,"role":19,"phone":20,"phoneExt":10,"email":21},"CONTACT","0031618843010","l.degraaff@erasmusmc.nl",{"name":23,"role":19,"phone":24,"phoneExt":10,"email":25},"Trui van Essen, MD","0031658869674","g.vanessen@erasmusmc.nl",[27],{"facility":15,"status":10,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Rotterdam","South Holland","3015GD","Netherlands","NL",{"type":34,"coordinates":35},"Point",[36,37],4.47917,51.9225,{"lat":37,"lon":36},[40],{"name":14,"role":19,"phone":20,"phoneExt":10,"email":21},{"type":16,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"dr. Laura C. G. de Graaff-Herder","MD, PhD",[45,47],{"name":46,"class":6},"Foundation for Prader-Willi Research",{"name":48,"class":49},"Prader-Willi Fonds","UNKNOWN","100399655","growth-hormone-study-in-adults-with-prader-willi-syndrome-100399655",false,"NCT04484051","Growth Hormone Study in Adults With Prader-Willi Syndrome","Growth Hormone Study in Adults With Prader-Willi Syndroom","GAP","Inclusion Criteria:\n\n* The patient is diagnosed with Prader-Willi syndrome (genetically confirmed)\n\nExclusion Criteria:\n\n* Non cooperative behaviour\n* Pregnancy\n* Known malignancies\n* Poorly controlled diabetes (HbA1c \\> 64 mmol\u002Fmol (8%))\n* Untreated obstructive sleep apnea (apnea-hypopnea index \\> 5)\n* Body mass index above 40 kg\u002Fm2\n* Upper-airway obstruction of any cause","ALL","18 Years",{"count":61,"type":62},25,"ESTIMATED","OBSERVATIONAL","The overall objective of this study is to measure the effect of growth hormone (GH) treatment on physical and psychosocial health in adults with Prader-Willi syndrome. Adults with PWS who have not been treated with GH during the past three years and who will start with GH treatment as part of regular patient care will be asked for informed consent to participate in this open-label prospective cohort study. We hypothesize that growth hormone treatment will improve the physical and psychosocial health.",[66],"Prader-Willi Syndrome",[68,69,70,71],"Prader-Willi syndrome","Growth hormone","Body composition","Cardiovascular disease","NOT_YET_RECRUITING","2023-02-15",{"date":75,"type":76},"2023-02-16","ACTUAL",{"date":78,"type":62},"2023-03-24",{"date":80,"type":62},"2026-10-01",{"name":5,"class":6},1]